Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 2021

NEXT STORY
SCYNEXIS Pivotal Phase 3 VANISH-303 Trial Results Published in Clinical Infectious Diseases Demonstrate Significant Superiority of Ibrexafungerp Over Placebo for Treatment of Vaginal Yeast Infection
PREV STORY
Insights on the Polymerase Chain Reaction Consumables Global Market to 2027 – Growing Adoption of Technological Advancements Presents Opportunities
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria

author_avatar
NASDAQ Market News

Cesca Therapeutics Strengthens Leadership Team and Board of Directors

Appoints Ms. Vivian Liu as Chief Operating Officer Elects Dr. Russell Medford to its ...

author_avatar
NASDAQ Market News

Magnesium Phosphate Market to hit $1.5bn by 2024: Global Market Insights, Inc.

Magnesium Phosphate Market Regional Analysis covering 20+ Countries and 18 Company Profiles (Jost Chemical, ...

author_avatar
NASDAQ Market News